Catalent Pharma Solutions and Supernus Pharmaceuticals have entered into an agreement where Catalent is the supplier of Trokendi XR extended release capsules for Supernus. Terms of the pact were not disclosed. Trokendi XR is a novel, oral, extended-release, once-daily formulation of topiramate for the treatment of epilepsy. Supernus recently received approval from the FDA and launched the product in the U.S. market. Trokendi XR delivers an extended-release form of topiramate, one of the most ef...